395104-30-0 Usage
Description
3-[3-[2-(1-Piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole is a complex organic compound with a molecular structure that features a 1H-indazole core, a phenyl group substituted with an ethoxy-linked piperidinyl group, and a 1,2,4-triazol-5-yl group. 3-[3-[2-(1-Piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole is characterized by its potential biological activities and may be of interest in the fields of pharmaceuticals and medicinal chemistry due to its structural features.
Uses
Used in Pharmaceutical Industry:
3-[3-[2-(1-Piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole is used as a potential therapeutic agent for various conditions due to its ability to modulate cellular signaling pathways and interact with specific biological targets. Its structural complexity and diversity allow for the possibility of being optimized for selectivity and potency against certain diseases.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 3-[3-[2-(1-Piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole serves as a starting point for the design and synthesis of new compounds with improved pharmacological properties. Its unique structure can be further modified to enhance its efficacy, bioavailability, and safety profile for specific therapeutic applications.
Used in Stress Response Modulation:
3-[3-[2-(1-Piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole may be used as a modulator of stress response pathways, such as the c-Jun N-terminal kinases (JNKs), which play a role in cellular responses to stress and are implicated in various diseases. By inhibiting JNK activation, this compound could potentially be used to treat conditions associated with excessive or dysregulated stress responses.
Used in Organ Transplantation:
As demonstrated with CC-401, a compound with similar structural features, 3-[3-[2-(1-Piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole may have applications in organ transplantation, particularly in reducing tissue damage and improving outcomes following procedures such as liver and renal transplantation. Its ability to decrease necrosis and apoptosis, as well as prevent acute renal failure, makes it a promising candidate for further research in this area.
references
[1] ma f y, flanc r s, tesch g h, et al. a pathogenic role for c-jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. journal of the american society of nephrology, 2007, 18(2): 472-484.[2] flanc r s, ma f y, tesch g h, et al. a pathogenic role for jnk signaling in experimental anti-gbm glomerulonephritis. kidney international, 2007, 72(6): 698-708.[3] bogoyevitch m a, arthur p g. inhibitors of c-jun n-terminal kinases—junk no more biochimica et biophysica acta (bba)-proteins and proteomics, 2008, 1784(1): 76-93.
Check Digit Verification of cas no
The CAS Registry Mumber 395104-30-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,9,5,1,0 and 4 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 395104-30:
(8*3)+(7*9)+(6*5)+(5*1)+(4*0)+(3*4)+(2*3)+(1*0)=140
140 % 10 = 0
So 395104-30-0 is a valid CAS Registry Number.
InChI:InChI=1S/C22H24N6O/c1-2-9-28(10-3-1)11-12-29-18-6-4-5-16(13-18)21-19-14-17(22-23-15-24-27-22)7-8-20(19)25-26-21/h4-8,13-15H,1-3,9-12H2,(H,25,26)(H,23,24,27)
395104-30-0Relevant articles and documents
Solid forms of a JNK inhibitor
-
Page/Page column 17, (2010/11/24)
The present invention provides solid forms of Compound (I), pharmaceutical compositions thereof, and methods for the treatment or prevention of diseases including, but not limited to a liver disease, cancer, a cardiovascular disease, a metabolic disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension, ischemia/reperfusion injury, central nervous system (CNS) injury/damage or a disease treatable or preventable by the inhibition of JNK. In particular, the invention relates to certain novel crystal forms of the compound 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene.
